Chipscreen(SH:688321) Xin Lang Cai Jing·2025-09-01 03:18Group 1 - The core viewpoint of the news is the performance and financial status of Microchip Biotech, which saw a stock price increase of 5.01% to 38.38 CNY per share, with a total market capitalization of 15.651 billion CNY [1] - Microchip Biotech's main business involves providing affordable, urgently needed innovative molecular entity drugs, with revenue composition being 75.92% from Sidabone, 21.30% from Siglitazone, and 2.04% from other sources [1] - The company is located in Shenzhen, Guangdong Province, and was established on March 21, 2001, with its listing date on August 12, 2019 [1] Group 2 - From the perspective of fund holdings, Minsheng Jianyin Fund has one fund heavily invested in Microchip Biotech, specifically the Minsheng Jianyin Selected Mixed Fund (690003), which reduced its holdings by 16,300 shares in the second quarter [2] - The Minsheng Jianyin Selected Mixed Fund currently holds 61,000 shares, accounting for 3.98% of the fund's net value, ranking it as the ninth largest holding [2] - The fund has achieved a year-to-date return of 50.88% and a one-year return of 73.04%, with a total fund size of 36.408 million CNY [2]